Business Context and Reporting Period
American Healthcare REIT, Inc. filed this Form 8-K on March 15, 2023, to disclose an updated estimated per share Net Asset Value (NAV) and a reduction in its quarterly distribution. The NAV calculation is based on a valuation date of December 31, 2022, performed by independent valuation firm Robert A. Stanger & Co., Inc. ("Stanger") in accordance with IPA Valuation Guidelines.
Key Financial Metrics
Estimated Per Share NAV: $31.40 (as of December 31, 2022).
Quarterly Distribution: Reduced from $0.40 to $0.25 per share (annualized rate of $1.00).
Asset Valuation Components (as of Dec 31, 2022):
- Appraised Properties and Other Properties: $2,596,087,000
- Trilogy Joint Venture Interest: $859,574,000
- Debt Investment: $80,197,000
- Management Company: $77,900,000
- Cash and Other Assets: $63,225,000
- Debt Liabilities: $(1,375,737,000)
- Other Liabilities: $(105,073,000)
Total Estimated Net Asset Value: $2,189,004,000
Fully Diluted Shares Outstanding: 69,712,000
Material Changes Versus Prior Period
The updated estimated per share NAV of $31.40 represents a decrease from the prior estimated NAV of $37.16 (adjusted for the November 2022 one-for-four reverse stock split) calculated as of December 31, 2021. Key drivers for the change include:
- Asset Value Decline: The estimated value of Appraised Properties decreased from $2.84 billion to $2.60 billion.
- Management Company Value: The estimated value of the Management Company dropped significantly from $135 million to $77.9 million.
- Liability Increases: Debt Liabilities increased from $1.31 billion to $1.38 billion, and Other Liabilities rose from $58.5 million to $105.1 million.
- Share Count Reduction: Fully diluted shares outstanding decreased from 277,040,000 to 69,712,000 due to the reverse stock split.
Guidance, Outlook, and Risks
Management Commentary: The Board reduced the quarterly distribution to $0.25 per share to preserve liquidity, align distributions with available cash flows, and support long-term strategic goals. The distribution reinvestment plan remains suspended.
Valuation Sensitivity: The filing includes a sensitivity analysis indicating that a 5.0% increase in discount and capitalization rates could lower the estimated NAV to $28.33, while a 5.0% decrease could raise it to $34.84.
Risks and Contingencies:
- Market Conditions: The valuation is sensitive to inflation, prevailing interest rates, and movements in capitalization rates.
- Pandemic Impact: Ongoing effects of the COVID-19 pandemic on healthcare real estate, occupancy, and tenant operations remain a risk.
- Limitations: The estimated NAV is not audited, does not represent GAAP book value, and does not reflect liquidation value or potential disposition costs.
Investor Verification Checklist
- Verify the impact of the $0.15 per share distribution cut on cash flow coverage and liquidity.
- Review the specific capitalization and discount rates used by Stanger for the 174 appraised properties and the Trilogy Joint Venture.
- Confirm the status of the "Recent Acquisitions" and "Pending Dispositions" included in the valuation at contracted transaction prices.
- Assess the sensitivity of the NAV to further increases in interest rates given the weighted average discount rates cited (e.g., 6.97% for Medical Office Properties).
- Monitor the suspension of the distribution reinvestment plan and its effect on share count and liquidity.